Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia

American Journal of Hematology

Volumn 84, Issue 12, 2009, Pages 849-850

  Papayannidis, Cristina ^a   Derenzini, Enrico ^a   Iacobucci, Ilaria ^a   Curti, Antonio ^a   Paolini, Stefania ^a   Cilloni, Daniela ^b   Baccarani, Michele ^a   Martinelli, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ASPARAGINASE; CD33 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MERCAPTOPURINE; METHOTREXATE; STEM CELL FACTOR; TRANSCRIPTION FACTOR PAX5; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASTHENIA; BLAST CELL; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER RECURRENCE; CASE REPORT; CHROMOSOME ANALYSIS; ERYTHROCYTE TRANSFUSION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KLEBSIELLA PNEUMONIAE; LEUKOCYTOSIS; LUNG INFECTION; MALE; PANCYTOPENIA; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADENINE NUCLEOTIDES; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; ASPARAGINASE; BONE MARROW; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYTARABINE; DAUNORUBICIN; HUMANS; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 73349099990     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21548     Document Type: Article

References (10)

1. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DANN synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-β-D- arabinofuranosyl) adenine. Cancer Res 1996;56:3030-3037.
2. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukaemia. J Clin Oncol 2006;24:1917-1923.
3. Burnett AK, Russell N, Kell JW, et al. A phase II evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 2004;104(suppl 1):248a. Abstract 869.
4. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase I-II study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-947.
5. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762-1769.
6. Chang JE, Medlin SC, Kahl BS, et al. Augmented and standard Berlin- Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. 2008;49:2298-2307.
7. Preti HA, Huh YO, O'Brien SM, et al. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer 1995;76:1564-1570.
8. Vitale A, Guarini A, Ariola C, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Hematologica 2007;92:342-348.
9. Lucio P, Gaipa G, van Lochem EG, et al. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted action investigation of minimal residual disease in acute leukemia: International standardization and clinical evaluation. Leukemia. 2001;15:1185-1192.
10. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001;98:988-994.